PCC Rokita SA

DB:229 Stock Report

Market Cap: €328.6m

PCC Rokita Valuation

Is 229 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 229 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 229 (€15.98) is trading below our estimate of fair value (€36.64)

Significantly Below Fair Value: 229 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 229?

Key metric: As 229 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 229. This is calculated by dividing 229's market cap by their current earnings.
What is 229's PE Ratio?
PE Ratio11.8x
Earningszł121.01m
Market Capzł1.43b

Price to Earnings Ratio vs Peers

How does 229's PE Ratio compare to its peers?

The above table shows the PE ratio for 229 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average11.2x
UZU Uzin Utz
10.5x2.1%€250.2m
ACT AlzChem Group
12.1x12.6%€606.5m
2HRA H&R GmbH KGaA
13.3x34.4%€127.3m
NTG Nabaltec
8.8x4.3%€122.8m
229 PCC Rokita
11.8x14.4%€1.4b

Price-To-Earnings vs Peers: 229 is expensive based on its Price-To-Earnings Ratio (11.8x) compared to the peer average (11.2x).

Price to Earnings Ratio vs Industry

How does 229's PE Ratio compare vs other companies in the European Chemicals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
229 11.8xIndustry Avg. 16.8xNo. of Companies11PE01224364860+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 229 is good value based on its Price-To-Earnings Ratio (11.8x) compared to the European Chemicals industry average (16.8x).

Price to Earnings Ratio vs Fair Ratio

What is 229's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

229 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.8x
Fair PE Ratio11.9x

Price-To-Earnings vs Fair Ratio: 229 is good value based on its Price-To-Earnings Ratio (11.8x) compared to the estimated Fair Price-To-Earnings Ratio (11.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 229 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€15.98
€21.62
+35.3%
12.8%€25.48€19.13n/a3
Nov ’25€17.90
€21.59
+20.6%
12.8%€25.44€19.10n/a3
Oct ’25€18.52
€22.83
+23.2%
11.7%€25.68€19.27n/a3
Sep ’25€19.46
€22.83
+17.3%
11.7%€25.68€19.27n/a3
Aug ’25€20.45
€22.81
+11.5%
11.6%€25.65€19.26n/a3
Jul ’25€20.60
€23.55
+14.3%
0.4%€23.65€23.46n/a2
Jun ’25€20.10
€23.55
+17.2%
0.4%€23.65€23.46n/a2
May ’25€23.10
€23.12
+0.07%
0.4%€23.21€23.02n/a2
Apr ’25€23.50
€23.12
-1.6%
0.4%€23.21€23.02n/a2
Mar ’25€21.90
€23.12
+5.6%
0.4%€23.21€23.02n/a2

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Compañía de Minas BuenaventuraA

US$3.1b

Engages in the exploration, development, construction, and operation of mineral processing business.

MBU

US$11.40

7D

-0.9%

1Y

37.3%

Arkema

€5.6b

Manufactures and sells specialty chemicals and advanced materials worldwide.

V1S

€74.30

7D

-4.7%

1Y

-20.2%

Central Asia Metals

UK£276.3m

Operates as a base metals producer.

9C3

UK£1.86

7D

-0.5%

1Y

-4.1%